ReviewMedicina (Kaunas, Lithuania)2024
Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
Review in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis.Dermatology and therapy · 2026Pooled it
- Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Tislelizumab-induced psoriasis in a patient with hepatocellular carcinoma: A case report.Experimental and therapeutic medicine · 2026Article
- Review
- Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities.Life (Basel, Switzerland) · 2025Review
- Dermatologic toxicities related to cancer immunotherapy.Toxicology reports · 2025Article
- Bullous Pemphigoid Overlapping Psoriasis Vulgaris: A Rare Case Report and Literature Review.Clinics and practice · 2025Review
- Toripalimab induces exacerbation of psoriasis in an esophageal cancer patient: a case report.Frontiers in oncology · 2025Article
- Case Report: Deep and durable response to talazoparib in germlineFrontiers in oncology · 2025Article
- Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.International journal of molecular sciences · 2024Review
- Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors.World journal of clinical cases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.